Business Insider

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET ...
Business Insider

Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood Test

Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field today There are approximately ...
Morningstar

Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood Test

Comprehensive epigenomic platform enables systematic and quantitative prediction of tumor gene expression from cell-free DNA Genes include key targets for next generation precision medicines, such as ...